These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30318269)

  • 1. Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study.
    Alperi-López M; Alonso-Castro S; Morante-Bolado I; Queiro-Silva R; Riestra-Noriega JL; Arboleya L; Ballina-García FJ
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):319-323. PubMed ID: 30318269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience.
    Maneiro JR; Perez-Pampin E; Salgado E; Carmona L; Gomez-Reino JJ
    Rheumatol Int; 2014 Aug; 34(8):1059-63. PubMed ID: 23893036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
    Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
    Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose tapering of biologic agents in patients with rheumatoid arthritis-results from a cohort study in Germany.
    Krause D; Krause C; Rudolf H; Baraliakos X; Braun J; Schmitz E
    Clin Rheumatol; 2021 Mar; 40(3):887-893. PubMed ID: 32822057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
    de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L
    Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.
    Hooijberg F; Layegh Z; Leeuw M; Boekel L; van den Berg SPH; Ruwaard J; Bastida C; Huitema ADR; Pel S; Elkayam O; de Vries A; Nurmohamed M; Rispens T; Dorlo TPC; Wolbink G
    Ther Drug Monit; 2024 Jun; 46(3):410-414. PubMed ID: 38287880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
    Mallick A; Fautrel B; Sagez F; Sordet C; Javier RM; Petit H; Chatelus E; Rahal N; Gottenberg JE; Sibilia J
    Rev Med Interne; 2017 Apr; 38(4):256-263. PubMed ID: 28161110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose down-titration of biological DMARDs in patients with rheumatoid arthritis over time and in daily clinical practice.
    Rodriguez-Rodriguez L; Leon L; Lamas JR; Gomez A; Vadillo C; Blanco M; Jover JA; Abasolo L
    Clin Exp Rheumatol; 2016; 34(5):872-879. PubMed ID: 27214094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.
    Lenert A; Lenert P
    Clin Rheumatol; 2017 Jan; 36(1):1-8. PubMed ID: 27896522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse in rheumatoid arthritis patients undergoing dose reduction and withdrawal of biologics: are predictable factors more relevant than predictive parameters? An observational prospective real-life study.
    Vittecoq O; Desouches S; Kozyreff M; Nicolau J; Pouplin S; Rottenberg P; Sens N; Lequerre T; Avenel G
    BMJ Open; 2019 Dec; 9(12):e031467. PubMed ID: 31857303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
    Notario Ferreira I; Ferrer González MA; Morales Garrido P; González Utrilla A; García Sanchez A; Soto Pino MJ; Suero Rosario E; Caro Hernández C; Añón Oñate I; Pérez Albaladejo L; Cáliz Cáliz R
    Reumatol Clin; 2017; 13(2):78-84. PubMed ID: 27174398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
    Kizaki K; Yamashita F; Hayashi T; Funakoshi N
    Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
    Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
    Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study.
    van der Maas A; Kievit W; van den Bemt BJ; van den Hoogen FH; van Riel PL; den Broeder AA
    Ann Rheum Dis; 2012 Nov; 71(11):1849-54. PubMed ID: 22504561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors.
    Brahe CH; Krabbe S; Østergaard M; Ørnbjerg L; Glinatsi D; Røgind H; Jensen HS; Hansen A; Nørregaard J; Jacobsen S; Terslev L; Huynh TK; Jensen DV; Manilo N; Asmussen K; Brown Frandsen P; Boesen M; Rastiemadabadi Z; Morsel Carlsen L; Møller JM; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2019 Jan; 58(1):110-119. PubMed ID: 30169706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.